News

Market Alert : Global Sell-Off Extends: Liquidity Fears and Growth Concerns Dominate

Market Close Commentary: 16 February 2022

By the end of the trading session on 16 February 2022, benchmark index ASX 200 settled in the green zone and settled at 7284.9, up 1.082% from the previous close. Out of 11 sectors on ASX, 9 sectors ended higher along with the S&P/ASX 200 Index. The Healthcare sector was the best performing sector on ASX, with a growth of 6.22% on 16 February 2022 and 1.15% in the past five days.

On the other hand, the energy and material sectors dropped by 0.743% and 0.359%, respectively.

 Copyright © 2022 Kapitales Research

Liontown Resources Limited (ASX: LTR) and Imugene Limited (ASX:IMU) were the top two gainers for the day with 17.985% and 12.727% growth in their share price, respectively.

LTR shares surged following the announcement that it signed a binding sales and purchase tern sheet with Tesla for the supply of Lithium Spodumene Concentrate from the new AU$473 million Kathleen Valley Lithium project in WA.

On the other hand, Netwealth Group Limited (ASX:NWL) and Hub24 Limited (ASX:HUB24) were the top two losers on ASX.

Netwealth Group also released its half-yearly results today and reported 17.1% growth in its revenue. However, it experienced a net loss of 1.8% during the period. EPS also dropped by 1.8% to AU11.1 cents per share.

Top performing Sectors for the day:

  • Healthcare (Up 6.221%)
  • A-REIT (Up 3.134%)

Worst performing sectors for the day:

  • Energy (Down 0.743 %)
  • Resources (Down 0.583%)

Factors Influencing Market on 16 February 2022:

  • ASX's performance on 16 February 2022 was driven by the half-yearly results announced by most companies.
  • There is an update in the market related to the withdrawal of Russian troops from the Ukraine border. However, there still exists uncertainty whether Russia would attack Ukraine.

Top 5 Gainers and Losers:

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Maven Capital Pty Ltd (AFSL No. 418504). The information contained in this article is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Suite 1A, Level 2, 802-808 Pacific Highway, Gordon NSW 2072, Australia | 1800 005 780 | info@kapitales.com.au.au